首页> 外文期刊>International Journal of Hematology and Oncology >TREATMENT OF METASTATIC BREAST CANCER WITH CAPECITABINE: EFFICACY AND TOXICITY

【24h】

TREATMENT OF METASTATIC BREAST CANCER WITH CAPECITABINE: EFFICACY AND TOXICITY

机译：卡培他滨治疗转移性乳腺癌的疗效和毒性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《International Journal of Hematology and Oncology》 |2016年第4期|共页
作者
BüLENT KARABULUT; ERDEM G?KER; GAMZE G. MüEZZ?NO?LU; NECMETT?N ?ZDEM?R; Rü?HAN USLU; ULUS A. ?ANLI; VEL?DD?N C. SEZG?N;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer [J] . TonyaliO., BenekliM., BerkV., Journal of Cancer Research and Clinical Oncology . 2013,第6期

机译：曲妥珠单抗和紫杉醇联合卡培他滨在HER2阳性转移性乳腺癌的一线治疗中的疗效和毒性
2. TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：TBCRC049：II期非随机性研究，以评估Tucatinib和Trastuzumab和Capecitabine的组合的安全性和功效，用于治疗Her2阳性乳腺癌TBCRC049中的百分声膜转移：II期非随机性研究，以评估安全性和疗效 Tucatinib和Trastuzumab和Capecitabine的组合治疗HER2阳性乳腺癌中的百分症转移
3. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: Efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group [J] . LückH.-J., DuBoisA., LoiblS., Breast cancer research and treatment. . 2013,第3期

机译：卡培他滨联合紫杉醇与表柔比星联合紫杉醇作为转移性乳腺癌的一线治疗：AGO乳腺癌研究小组进行的一项随机III期试验的疗效和安全性结果
4. Non-toxic approach for treatment of breast cancer and its cutaneous metastasis: Capecitabine (Xeloda™) enhanced photodynamic therapy in a murine tumor model [C] . Sanjay Anand, Anton Denisyuk, Taylor Bullock, Conference on optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy . 2018

机译：治疗乳腺癌及其皮肤转移的无毒方法：卡培他滨（Xeloda™）在小鼠肿瘤模型中增强了光动力治疗
5. Cost-Benefit Analysis of Nanoparticle Albumin-Bound Paclitaxel versus Solvent-Based Paclitaxel for the Treatment of Metastatic Breast Cancer in the United States [D] . Vichansavakul, Kittaya 2013

机译：纳米白蛋白结合紫杉醇与溶剂型紫杉醇在美国治疗转移性乳腺癌的成本效益分析
6. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial [O] . S Stintzing, L Fischer von Weikersthal, U Vehling-Kaiser, 2011

机译：卡培他滨诱导的皮肤毒性与转移性结直肠癌患者治疗效果的相关性：德国AIO KRK-0104试验结果
7. PCN24 COST-EFFECTIVENESS ANALYSIS OF LAPATINIB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE AND OF TRASTUZUMAB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE IN THE TREATMENT OF METASTATIC BREAST CANCER UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE [O] . Teich V, Passos RBF, Teich N, 2009

机译：巴西卡培他汀对卡西他滨对卡培他滨单独治疗的拉帕替尼和卡培他滨对卡培他滨单独治疗的曲妥珠单抗的PCN24成本效益分析

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号